GlassScriptPhysician profile
Mahnaz Saoudian
NPI 1447451299
$8,504.13
in general payments reported to CMS, 2019-2025
23 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2020: $399 · 2021: $1,060 · 2022: $1,483 · 2023: $1,570 · 2024: $1,720 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,500 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,499.96 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,881.85 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Ucb, INC. | $1,290.68 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $1,064.79 | 2019-2025 | Otezla, Enbrel, Otezla |
| Novartis Pharmaceuticals Corporation | $874.86 | 2019-2025 | |
| Janssen Biotech, INC. | $498.52 | 2019-2024 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $496.59 | 2019-2025 | Taltz |
| Astrazeneca Pharmaceuticals LP | $254.97 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $193.03 | 2020-2025 | Orencia |
| Pfizer INC. | $180.80 | 2019-2025 | |
| Horizon Therapeutics Plc | $117.82 | 2021 | |
| Janssen Scientific Affairs, LLC | $108.75 | 2025 | Tremfya |
| Glaxosmithkline, LLC. | $97.37 | 2019-2025 | Benlysta, Nucala |
| Radius Health, INC. | $93.35 | 2019-2025 | Tymlos |
| Organon LLC | $88.69 | 2023-2025 | Hadlima, Renflexis |
| Mallinckrodt Hospital Products INC. | $59.99 | 2025 | Acthar |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $54.57 | 2024-2025 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $39.96 | 2019 | |
| Genentech USA, INC. | $21.56 | 2023 | Actemra |
| Alvogen INC | $18.98 | 2024 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.40 | 2023 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $16.74 | 2022 | |
| Sebela Pharmaceuticals INC. | $16.43 | 2019 | |
| Hikma Pharmaceuticals USA | $16.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahnaz Saoudian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.